Herein, we present a novel method of asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) determination within biological samples using protein precipitation and LC/MS/MS. Chromatographic separation of ADMA and SDMA was successfully performed using a silica column with optimized elution, or mobile phase, of 10 mM ammonium acetate buffer H 2 O/methanol/acetonitrile (20/35/45, v/v) at pH 4. The calibration ranges were 0.50 -50.0 µg·mL -1 , and good linearities were obtained for all compounds ( r > 0.99). The intra-and inter-assay accuracies with recoveries and precisions at three concentration levels (i.e. 1.00, 5.00 and 25.0 µg·mL -1 ) were better than 86.9% and 7.36%, respectively. The analytical performance of the method was evaluated by determination of compounds in plasma, urine and tissues from male BALBc/J mice. For the first time, we were able to characterize the distribution of ADMA, SDMA and AD-MA/SDMA in plasma, urine, brain, heart, kidneys, liver, lungs, pancreas and spleen. Additionally, we demonstrated that the ADMA/SDMA ratio in the brain was approximately 10-fold lower than all the other biological samples. Only 10 µL of plasma, 1 µL of urine and about 25 mg of tissues were required. These results suggest that the developed methodology was useful in ADMA and SDMA determination within biological samples.
Introduction
Asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) are methylated by protein arginine (Arg) methyltransferases (PRMTs) from Arg and metabolized by dimethylarginine dimethylaminohydrolase (DDAH) (Figure 1 ) [1, 2] . ADMA and SDMA are endogenous uremic toxins that are associated with chronic kidney disease (CKD) and renal inflammation [3] [4] [5] [6] . In fact, Toyohara, et al. reported that ADMA was a biomarker for CKD patients [7] . In previous studies, the biological reactions associated with these conditions have been primarily attributed to ADMA, whereas the role of SDMA has been overlooked. However, it has recently been reported that a ratio of Arg, ADMA and SDMA is important in the pathophysiological analysis of cardiovascular diseases, reduced renal functions and other diseases [6, 8, 9] . Therefore, a methodology for detecting both ADMA and SDMA is warranted. The analytical methods of ADMA and SDMA have been developed using several techniques. The enzyme-linked immunosorbent assay (ELISA) method has been shown to detect cross-reactivity with SDMA [10] , albeit with low sensitivity. Given that ADMA and SDMA are structural isomers and the molecular weight is identical at 202.1, chromatographic separation using high performance liquid chromatography (HPLC) with ultra violet (UV), radioimmunoassay and fluorescence (FL) detection was shown to be necessary [11] [12] [13] [14] [15] . The first HPLC method for dimethylarginine detection was reported in 1999 [12] . In 2000, an HPLC method with FL detection was developed, which had high sensitivity, reliability, and good separation of ADMA and SDMA [13, 15] . Unfortunately, these HPLC methods are very time consuming. Since 2000, ADMA and SDMA have also been detected by liquid chromatography/mass spectrometry (LC/MS) and liquid chromatography/tandem mass spectrometry (LC/ MS/MS) [16] [17] [18] [19] [20] [21] . Although detection of a selective product ion with MS/MS fragmentation can be difficult, Bishop, et al. and Zotti, et al. have been reported that the selective product ions for ADMA and SDMA are at m/z 203→46 and 203→172, respectively [17] [18] [19] . Additionally, though these methods are more sensitive, ADMA and SDMA have the different pattern of dissociation using various MS system. Di Gangi, et al. have developed a reliable method using ultra per-formance LC/MS /MS that is simple and has a short analytical time [21] . This method is sensitive, however preparation for derivatization is time consuming, and ADMA and SDMA have not been separated successfully. The use of capillary electrophoresis (CE) for ADMA and SDMA analysis has also been reported. In fact, recent reports describe using CE/MS/MS and CE/UV for determination of ADMA and SDMA [22, 23] . Due to the high number of theoretical plates, these methods have good separation of ADMA and SDMA, high sensitivity and reliability. However, CE is only appropriate for determining ADMA and SDMA in plasma (i.e. it is not applicable in tissues or any biological samples). Additionally, homoarginine is not a suitable internal standard (IS) because it is detected in biological samples. Thus, a simple, un-deriva-tive, highly sensitive and reliable method using LC/MS /MS for ADMA and SDMA determination, which can also separate isomers and determine ADMA and SDMA in biological samples, is warranted. The purpose of the present study is to: 1) develop a simple, sensitive and reliable method for ADMA, SDMA, Arg and creatinine (Cr) determination in plasma, urine and tissues, and 2) to determine the distribution of ADMA and SDMA in biological samples of mice. Herein, we have described the chromatographic separation of ADMA and SDMA following HPLC optimization.
Experimental

Chemicals
An ADMA standard was obtained from Sigma-Aldrich (St. Louis, MO). SDMA and Cr standards were obtained from Wako Pure Chemical Industries (Tokyo, Japan). Arg and L-arginine- 13 
Mass spectrometry system and conditions
The MS system was a Thermo Fisher Scientific TSQ Quantum Ultra triple quadrupole mass spectrometer equipped with a heated electrospray ionization (HESI) source. The operating conditions were optimized for each compound by continuously infusing standard solutions dissolved in water (10.0 µg·mL -1 ) at a rate of 5 µL·min -1 . Our final analytical conditions for MS are summarized in Table 1 . HESI was performed in a positive ion mode (pos) for ADMA, SDMA, Arg, Cr, IS1 and IS2. Samples were analyzed using the selected reaction monitoring (SRM) mode, and employing the transition of the (M + H) + precursor ions to their product ions. The MS/MS transitions were determined in the full scan mode (m/z 30 -250). For the MS/MS analysis, the optimized tube lens offsets and collision energies for collision-induced dissociation (CID) of ADMA, SDMA, Arg, Cr, IS1 and IS2 are summarized in Table 1 . The pos HESI spray voltages were 1,500 V, the heated capillary temperature was 380˚C, the sheath gas pressure was 65 psi, the auxiliary gas setting was 20 psi and the heated vaporizer temperature was 380˚C. Both the sheath gas and auxiliary gas were nitrogen gas. The collision gas was argon at a pressure of 1.2 mTorr. The LC/MS/MS system was controlled by the Xcalibur software (Thermo Fisher Scientific, San Jose, CA) and data were collected with the same software.
Liquid chromatography system and conditions
A NANOSPACE SI-2 LC system comprising an LC pump, auto-sampler, column oven and on-line degasser (Shiseido, Tokyo, Japan) was used. The separations were performed on a Mightysil Si (250 mm × 2 mm I.D., 5 µm particle size) analytical column coupled with a CAP-CELL PAK C18 MG II (10 mm × 2 mm I.D., 3 µm particle size) (Shiseido, Tokyo, Japan) guard column maintained at 40˚C ( Table 1 ). 
Calibration
All peaks were integrated automatically by the Xcalibur software. The ADMA, SDMA and Arg amounts were calculated from the calibration curves using the ratios of their peak areas to that of IS1, and the Cr amounts were calculated from the calibration curve using the ratios to IS2. The range used for the calibration curves of ADMA, SDMA, Arg and Cr was between 0.500 -50.0 µg·mL , respectively).
Validation of the analytical method
To determine the accuracy and precision, the newly developed method was validated at three concentrations (1.00, 5.00 and 25.0 µg·mL -1 ) using five samples on three different days. The accuracies and precisions of the method were determined through intra-and inter-day analyses. Accuracy was calculated from the percentage deviation from the mean of the true value, and precision was expressed as the relative error and coefficient of variation (CV, %). The data were validated based on FDA's Guidance for Industry: Bioanalytical Method Validation guidelines.
Animals and collection of biological samples
Male BALBc/J mice ( 3 n = ) were kept in a room with a 12-h/12-h light-dark cycle (light cycle from 9:00 to 21:00) at 23˚C -25˚C and provided water and food ad libitum. All procedures used for LC/MS/MS were approved by the committee on the Care and Use of Experimental Animals, Tohoku University, in accordance with the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health. To demonstrate the biological distribution of ADMA and SDMA, we collected 9 biological samples (plasma, urine and 7 tissues). Mice were first anesthetized with so- dium pentobarbital. Blood was then collected via retroorbital bleeding, transferred into a 1.5-mL plastic tube with 30 µL of 10 mM ethylenediaminetetraacetic acid, immediately centrifuged at 16,400 × g for 10 min, and the supernatant was transferred into a new plastic tube. Mice were then rapidly perfused transcardially with cold saline through the left ventricle and thereby sacrificed. Subsequently, urine and tissues (brain, liver, kidneys, lungs, pancreas, spleen and heart) were quickly removed. All plasma, urine and pulverized tissues were stored at -80˚C.
Sample preparation of plasma and urine
Sample preparation of plasma and urine for LC/MS/MS was performed as follows. Plasma (10 µL) and urine (1 µL) were transferred into a 1.5-mL plastic tube. Then, 50 µL of internal standard 1 (IS1; Arg-13 C 6 at 10 µg·mL -1 ) and IS2 (Cr-d 3 at 1 µg·mL ), and 250 µL of 0.1% HCOOH/CH 3 CN were added. The resulting mixture was homogenized for 30 s in an ultrasonic bath. After centrifugation at 16,400 × g for 10 min, the supernatant was transferred into a new plastic tube and evaporated at 60˚C until dry under nitrogen gas stream. The residue was reconstituted in 50 µL of mobile phase, vortexed for 30 s, and passed through a filter (pore size: 0.2 µm, YMC). Subsequently, 1 µL of the filtered solution was injected into the LC/MS/MS system for analysis. The concentrations of the individual compounds were calculated from a regression of the calibration curves. The values were calculated as the mean ± standard deviation (SD). Cr was used as a biomarker to correct for different volumes or urine produced per day [24] . The corrected values of ADMA, SDMA and Arg in urine were calculated by the concentration ratios of the individual compounds (µg·mL -1 ) to the Cr concentration in urine (µg·mL -1 ).
Sample preparation of tissues
For LC/MS/MS analysis, tissue preparation based on previously described methodology [25] . Approximately 25 mg of each tissue was transferred into a 2-mL plastic tube, and 1000 µL of 0.1% HCOOH/CH 3 CN, 50 µL of internal standard 1 (IS1; Arg-13 C 6 at 10 µg·mL gation at 16,400 × g for 10 min, the supernatant was transferred into a new plastic tube and the preparations were following as described above.
Statistical analyses
For statistical analysis, we use Microsoft Office Excel 2007 software. The values were calculated as the mean ± SD. [26] , and some pervious methods selected different product ion [18, 19] . In our MS system, the product ions were as follows: m/z 40.1 for ADMA and m/z 129.1 for SDMA. However, these ions were not selective and not the highest ions for ADMA and SDMA determination. Consequently, a chromatographic separation of ADMA and SDMA was necessary in our study. Quantification analyses were performed in the SRM mode owing to the high selectivity and sensitivity of SRM data acquisition, in which transitions from the precursor ion into the product ion were monitored at: m/z 203.1→70. The results of retention and chromatographic separation are shown in Figure 3 . Previously, Paglia, et al. described chromatographic separation techniques for ADMA and SDMA using a silica column [20] . Thus, additional conditions of the mobile phase were tested to obtain better retention and separation of ADMA and SDMA. Using either MeOH or CH 3 CN as the mobile phase did not result in a good separation of ADMA and SDMA. Retention in MeOH was much shorter than in CH 3 CN because of interactions of ADMA and SDMA with the silica column was stronger in MeOH than in CH 3 CN. Although the Rs value increased depending on the percentage of MeOH, all of the peaks had poor shapes due to tailing (data not shown). On the other hand, using a mixture of MeOH and CH 3 CN rather than MeOH or CH 3 CN alone resulted in better separation, retention and peak shapes. In fact, 45% of CH 3 CN produced the best retention and Rs value (Rs = 1.62). Because of hydrophilic interactions, the distribution of ADMA and SDMA between the silica column and MeOH was too weak and CH 3 CN was too strong. Thus, a mixture of MeOH and CH 3 CN results in the best retention and separation of ADMA and SDMA. Furthermore, retention time is important for high-throughput analysis. In 45% of CH 3 CN, retention time was significantly increased for both AD-MA and SDMA due to the strong hydrophobicity of CH 3 CN, which retained the targeted compounds on the silica column.
Results and discussions
MS/MS and LC optimization
Additionally, pH dramatically affected the retention, separation and peak shapes. ADMA and SDMA were strongly retained at pH 5 and over. The Rs value at pH 3.5 was very low (Rs = 1.03) and the peak shapes and intensity were worse at pH 4.5 and over. The flow rate was determined from the Rs value of ADMA and SDMA. The optimal Rs value was 1.5 at a flow rate of 400 µL·min -1 . The best retention, separation and peak shapes were achieved at pH 4 and a flow rate of 400 µL·min 
Limit of quantification (LLOQ) and lower limit of detection (LLOD)
The lower limit of quantification (LLOQ) was considered as the lowest concentration that was measurable with a CV of >20 and a signal-to-noise (S/N) ratio of >10. The lower limit of detection (LLOD) was defined as the concentration with an S/N of 3. The analytical procedure was sensitive with LLOQ and LLOD values for ADMA, SDMA, Arg and Cr of 2.47, 2.47, 2.87 and 4.42 µmol·L -1 and 0.742, 0.742, 0.862 and 1.33 µmol·L -1 , respectively. The LLOD values obtained using our methodology were similar to those previously reported for ADMA and SDMA determination in biological samples [23] . However, the previously reported methodology required 100 µL of plasma, whereas our methodology required only 10 µL of plasma and 1 µL of urine. These results suggest that the sensitivity of our novel methodology was 10-fold greater than the previously reported methodology.
Linearity
The linearity of the calibration curves was evaluated using seven concentrations (0.250, 0.500, 1.00, 2.50, 5.00, 25.0 and 50.0 µg·mL , respectively) ( Table 2) . A linear regression analysis was performed on these portions of the curves, and it was found that the correlation coefficient was greater than 0.999 for all analytes.
Accuracy and precision
The results for the accuracy and precision are shown in Tables 3 and 4 , respectively. The intra-and inter-day accuracies ranged from 86.9% to 112% for the three concentrations used with all of the compounds. The intra-and inter-day precisions ranged from 0.19% to 7.36% for the three concentrations used with all of the compounds. These results indicate that our methodology has good reliability and repeatability. Validation was determined by spiking the standard compounds in plasma. Generally, validation of analytical methods is necessary, since the effects of ion suppression are variable in different types of tissues, and this is achieved by spiking each tissue sample. In our methodology, matrix effects could be avoided by using a silica column and the optimal mobile phase, which allows for chromatographic separation of ADMA and SDMA in several biological Table 5 . Although, all compounds were detected, some samples contained analytes at concentration levels outside the linear working range. These samples were adjusted into the working range of the calibration and were reanalyzed. The SRM chromatograms of biological sample are shown in Figure 5 . ADMA and SDMA levels were high in urine, kidneys, liver, pancreas and spleen. With the exception of low liver levels, Arg had similar urine and tissue levels as ADMA and SDMA. Cr levels were high in plasma, urine, brain, heart and pancreas. In previous studies, Arg/ADMA or ADMA + SDMA/monomethylarginine (MMA) ratios were described to have an important role evaluating disease progression [27] . Therefore, we calculated ADMA/SDMA ratios for tissue comparisons ( Table 5) . ADMA/SDMA ratios in the brain and plasma were lower than in the other tissues. The present study is the first to demonstrate lower level of ADMA/SDMA in the brain. DDAH is an enzyme that is known to metabolize endogenous nitric oxide synthase (NOS) inhibitors such as MMA and ADMA to citrulline [28] . The gene expression of DDAH I and II has been reported by Tra et al., and DDAH I have been more distributed in the brain than the other organs [29] . In addition, DDAH I and NOS were up-regulated in neurons following nerve injury [30] . These reports indicated that ADMA might be expeditiously metabolized by DDAH I in the brain, and the central nerves system might be protected by the low concentration of ADMA from the affection of NOx via the inhibition with NOS. Although the reason and mechanism for these findings cannot be elucidated in the present study, the data suggests that the brain and plasma may have high levels of SDMA in relation to ADMA. It has been suggested that the relative value is just as important as the absolute value for revealing the mechanisms of ADMA and SDMA. Thus, our novel methodology proved to be useful in detecting ADMA and SDMA in various biological samples with high sensitivity and selectivity.
Concluding remarks
We have developed a methodology for ADMA and SDMA determination in biological samples using LC/ MS/MS. Furthermore, it was validated that this methodology can determine ADMA and SDMA levels with high sensitivity and reliability. This methodology is the first of its kind that can determine tissue distribution of ADMA and SDMA with good separation. Additionally, this methodology requires small sample sizes, specifically only 10 µL of plasma, 1 µL of urine and about 25 mg of tissues were required in the present study. Furthermore, the ADMA/SDMA ratio was found to be lower in the brain than in any other tissues. Although the mechanism for this finding is unclear, the developed methodology was useful in determining ADMA and SDMA levels in biological samples.
